Glioblastoma Patients Who Respond to Targeted Therapy Identified
Posted on Sunday, November 13 @ W. Europe Standard Time by webmaster |
|
The key to whether glioblastoma patients respond to targeted therapy with Tarceva (erlotinib) or Iressa (gefitinib) may be whether their tumors express two key molecular markers...
The key to whether glioblastoma patients respond to targeted therapy with Tarceva (erlotinib) or Iressa (gefitinib) may be whether their tumors express two key molecular markers. If the markers are there, the patients are more than 50 times more likely to respond than if they aren't, reported Paul Mischel, M.D., of the University of California at Los Angeles and colleagues in the Nov. 10 issue of the New England Journal of Medicine. What's more, possession of the two markers extended life by almost a factor of four after treatment with the two drugs, they said...
Read more at MedPage Today
|
| |
|
